TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E-mutant metastatic colorectal cancer.

被引：0
|
作者：
Kotani, Daisuke
Kagawa, Yoshinori
Matsubara, Yuki
Bando, Hideaki
Harada, Kazuaki
Takahashi, Naoki
Mihara, Yoshiaki
Nakayama, Izuma
Izawa, Naoki
Kawakami, Takeshi
Masuishi, Toshiki
Hasegawa, Hiroko
Ohta, Takashi
Wakabayashi, Masashi
Yoshino, Takayuki
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Osaka Gen Med Ctr, Dept Gastroenterol Surg, Osaka, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[5] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[6] Saitama Canc Ctr, Saitama, Japan
[7] Saiatama Med Univ Int Med Ctr, Hidaka, Japan
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[9] St Marianna Univ Sch Med, Kawasaki, Kanagawa, Japan
[10] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Natl Hosp Org Osaka Natl Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[13] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
[14] Natl Canc Ctr Hosp East, Div Promot Drug & Diagnost Dev, Kashiwa, Chiba, Japan
[15] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS264
引用
收藏
页码：TPS264 / TPS264
页数：1
相关论文
共 50 条
  • [41] Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer.
    Taylor, Matthew H.
    Leidner, Rom S.
    Bell, Richard Bryan
    Fox, Bernard
    Xiao, Hong
    Couey, Marcus
    Baker, Andrew
    Morris, George
    Rushforth, Lessli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Martina Eriksen
    Per Pfeiffer
    Kristoffer Staal Rohrberg
    Christina Westmose Yde
    Lone Nørgård Petersen
    Laurids Østergaard Poulsen
    Camilla Qvortrup
    BMC Cancer, 22
  • [43] Rechallenge with cetuximab 1 irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with
    Daniele, Rossini
    Daniele, Santini
    Chiara, Cremolini
    Lisa, Salvatore
    Sara, Lonardi
    Emanuela, Dell' Aquila
    Giuseppe, Aprile
    Fotios, Loupakis
    Bruno, Vincenzi
    Francesca, Battaglin
    Vanessa, Buoro
    Emiliano, Tamburini
    Deborah, Basile
    Domenico, Corsi
    Iacopo, Fioroni
    Gianluca, Masi
    Carlotta, Antoniotti
    Beatrice, Borelli
    Marzia, Del Re
    Giuseppe, Tonini
    Alfredo, Falcone
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Eriksen, Martina
    Pfeiffer, Per
    Rohrberg, Kristoffer Staal
    Yde, Christina Westmose
    Petersen, Lone Norgard
    Poulsen, Laurids Ostergaard
    Qvortrup, Camilla
    BMC CANCER, 2022, 22 (01)
  • [45] Molecular characterization and subsequent treatments after encorafenib-cetuximab plus /- binimetinib in BRAF V600E-mutated colorectal cancer.
    Ros Montana, Javier
    Navarro, Victor
    Comas, Raquel
    Garcia, Ariadna
    Saoudi Gonzalez, Nadia
    Baraibar, Iosune
    Salva, Francesc
    Vivancos, Ana
    Tabernero, Josep
    Elez, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
    Tabernero, J.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. Sang
    Steeghs, N.
    Guren, T. K.
    Arkenau, H-T.
    Garcia-Alfonso, P.
    Gollerkeri, A.
    Pickard, M.
    Maharry, K.
    Christy-Bittel, J. L.
    Anderson, L.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 868 - 868
  • [47] Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
    Ros, Javierd
    Saoudi, Nadia
    Baraibar, Iosune
    Salva, Francesc
    Tabernero, Josep
    Elez, Elena
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [48] Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
    Sorah, Jonathan D.
    Moore, Dominic T.
    Reilley, Matthew J.
    Salem, Mohamed E.
    Triglianos, Tammy
    Sanoff, Hanna K.
    McRee, Autumn J.
    Lee, Michael S.
    ONCOLOGIST, 2022, 27 (12): : 1006 - E930
  • [49] A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
    Riely, Gregory J.
    Smit, Egbert F.
    Ahn, Myung-Ju
    Felip, Enriqueta
    Ramalingam, Suresh S.
    Tsao, Anne
    Johnson, Melissa
    Gelsomino, Francesco
    Esper, Raymond
    Nadal, Ernest
    Offin, Michael
    Provencio, Mariano
    Clarke, Jeffrey
    Hussein, Maen
    Otterson, Gregory A.
    Dagogo-Jack, Ibiayi
    Goldman, Jonathan W.
    Morgensztern, Daniel
    Alcasid, Ann
    Usari, Tiziana
    Wissel, Paul
    Wilner, Keith
    Pathan, Nuzhat
    Tonkovyd, Svitlana
    Johnson, Bruce E.
    FUTURE ONCOLOGY, 2024, 20 (16) : 1047 - 1055
  • [50] Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)
    Vogel, Arndt
    Hegewisch-Becker, Susanna
    Prager, Gerald
    Folprecht, Gunnar
    Stahl, Michael
    Kopetz, Scott
    Grothey, Axel
    van Cutsetn, Eric
    Yaeger, Rona
    Wasan, Harpreet
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Loupakis, Fotios
    Hong, Y.
    Steeghs, Neeltje
    Guren, Tormod Kyrre
    Arkenau, Hendrik-Tobias
    Garcia-Alfons, Pilar
    Sandor, Victor
    Christy-Bittel, Farina
    Anderson, Lisa
    Tabernero, Josep
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 55 - 55
12345